What is an IND Application (Investigational New Drug Application)
In the pharmaceutical industry, new drugs must undergo rigorous evaluation before they can be tested in humans. One of the most important regulatory steps in this process is the Investigational New Drug Application (IND). The IND allows pharmaceutical companies to begin clinical trials and ensures that investigational drugs are safe enough for human testing while protecting study participants.
Responding to FDA Form 483 Observations After a Drug CGMP Inspection
Regulatory checks are very essential in the aspect of making sure that pharmaceutical producers are adhering to the existing requirements of Good Manufacturing Practice (CGMP). In an inspection, U.S. Food and drug administration (FDA) might find conditions that may be against regulatory provisions. Such results are reported in the FDA Form. 483 – Inspectional Observations.
Understanding the FDA Draft Guidance on Biosimilar Development and the BPCI Act (Revision 4)
The U.S. Food and Drug Administration (FDA) released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) in March 2026 to clarify regulatory expectations for biosimilar and interchangeable biological products.
What is Quality by Design (QbD) in Regulatory Affairs?
Quality by Design (QbD) in Regulatory Affairs is a systematic, science-based approach to pharmaceutical development that focuses on building quality into a product from the earliest stages rather than testing it at the end.
What is a Pre-IND Meeting for US FDA?
A Pre-IND meeting for the US FDA is a formal meeting between a drug sponsor and the U.S. Food and Drug Administration (FDA) that takes place before submitting an Investigational New Drug (IND) application. The purpose of this meeting is to obtain regulatory guidance on the planned preclinical studies, clinical trial design, manufacturing information, and overall development strategy.